AT
Therapeutic Areas
Lyell Immunopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Rondecabtagene autoleucel (ronde-cel, LYL314) | Aggressive Large B-Cell Lymphoma (Third-line or Later) | Pivotal |
| LYL273 | Refractory Metastatic Colorectal Cancer (mCRC) and other GCC-expressing cancers | Phase 1 |
Leadership Team at Lyell Immunopharma
LS
Lynn Seely, M.D.
President and Chief Executive Officer
JA
Jarrad Aguirre, M.D., M.B.A.
Senior Vice President, Medical Affairs
SH
Stephen Hill, M.B.A.
Chief Operating Officer
GL
Gary Lee, Ph.D.
Chief Scientific Officer
MM
Mark Meltz, J.D.
General Counsel and Corporate Secretary
BS
Bryan Selby, M.S.
Senior Vice President, Clinical Development Operations
SS
Smital Shah
Chief Financial and Business Officer
DS
David Shook, M.D.
Chief Medical Officer
RK
Rick Klausner, M.D.
Founder & Chairman of the Board
CM
Crystal Mackall, M.D.
Founder